Nurix Therapeutics, Inc.

NASDAQ:NRIX

14.08 (USD) • At close April 17, 2024
Bedrijfsnaam Nurix Therapeutics, Inc.
Symbool NRIX
Munteenheid USD
Prijs 14.08
Beurswaarde 835,190,400
Dividendpercentage 0%
52-weken bereik 4.22 - 18.12
Industrie Biotechnology
Sector Healthcare
CEO Dr. Arthur T. Sands M.D., Ph.D.
Website https://www.nurixtx.com

An error occurred while fetching data.

Over Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable

Vergelijkbare Aandelen

MaxCyte, Inc. logo

MaxCyte, Inc.

MXCT

3.94 USD

Immunovant, Inc. logo

Immunovant, Inc.

IMVT

28.43 USD

Atara Biotherapeutics, Inc. logo

Atara Biotherapeutics, Inc.

ATRA

0.715 USD

OptimizeRx Corporation logo

OptimizeRx Corporation

OPRX

9.53 USD

Janux Therapeutics, Inc. logo

Janux Therapeutics, Inc.

JANX

47.96 USD

Immatics N.V. logo

Immatics N.V.

IMTX

10.23 USD

Seer, Inc. logo

Seer, Inc.

SEER

1.69 USD

Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc.

KPTI

1.38 USD

Nautilus Biotechnology, Inc. logo

Nautilus Biotechnology, Inc.

NAUT

2.43 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)